Publications by authors named "S F Chew"
Background: The emergence of induced pluripotent stem cells (iPSCs) offers a promising approach for replacing damaged neurons and glial cells, particularly in spinal cord injuries (SCI). Despite its merits, iPSC differentiation into spinal cord progenitor cells (SCPCs) is variable, necessitating reliable assessment of differentiation and validation of cell quality and safety. Phenotyping is often performed via label-based methods including immunofluorescent staining or flow cytometry analysis.
View Article and Find Full Text PDFArticle Synopsis
- Studies link living near major roads to a higher risk of Alzheimer's disease (AD), but the exact mechanisms are unclear.
- Exposure to diesel emissions (DE) was analyzed in olfactory mucosa cells from both healthy individuals and AD patients, revealing that AD cells showed nearly four times greater sensitivity to DE.
- DNA methylation patterns changed in response to DE exposure, identifying potential biomarkers and pathways involved, particularly highlighting the role of NRF2 signaling in cellular responses to air pollution.
Background: Packed red blood cell (pRBC) transfusions in patients undergoing surgery for cancer are given to treat anemia or acute hemorrhage. Evidence indicates that pRBC transfusions are associated with poor perioperative and oncological outcomes. The ARCA-1 (Perioperative Care in the Cancer Patient-1) study was designed to test the association between perioperative pRBC transfusions and postoperative morbidity and mortality in patients undergoing cancer surgery.
View Article and Find Full Text PDFBackground: People living with ALS (plwALS) experience motor control loss, speech/swallowing difficulties, respiratory insufficiency, and early death. Advancing disease stage is typically associated with a greater burden on the health care system, and delays in diagnosis can result in substantial health care resource utilization (HCRU).
Objective: To estimate HCRU and cost burden of plwALS across disease stages from a US payer perspective we assessed HCRU and costs in early-, mid-, and late-stage ALS.